# Evaluating the Combined Effect of Oral Premedications on Inferior Alveolar Nerve Block Effectiveness

> **NCT07146997** · PHASE3 · COMPLETED · sponsor: **Zahoor khan** · enrollment: 96 (actual)

## Conditions studied

- Symptomatic Irreversible Pulpitis

## Interventions

- **DIETARY_SUPPLEMENT:** Patients in this group will receive an oral placebo (e.g., sugar tablet or inert capsule) 1 hour before the IANB
- **DRUG:** Patients will receive ibuprofen (400-600 mg, standard therapeutic dose) orally, 1 hour prior to IANB
- **DRUG:** Group III - Serratiopeptidase Group
- **COMBINATION_PRODUCT:** Group IV - Combination Group (Ibuprofen and Serratiopeptidase)

## Key facts

- **NCT ID:** NCT07146997
- **Lead sponsor:** Zahoor khan
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-23
- **Primary completion:** 2024-11-23
- **Final completion:** 2024-11-23
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2025-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07146997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07146997, "Evaluating the Combined Effect of Oral Premedications on Inferior Alveolar Nerve Block Effectiveness". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07146997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*